BOA™ Biomedical’s GARNET™ therapeutic product begins First in Human clinical trial

Excerpt from the Press Release:

CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ –BOA Biomedical, a Miraki™ Innovation company, focused on rapidly diagnosing and treating some of the world’s deadliest infectious diseases has announced that the company will begin its First in Human clinical trial for GARNET. GARNET is an extracorporeal blood cleansing therapeutic capable of removing a significant number of pathogens and their toxic inflammation-triggering debris directly from a patient’s blood. BOA’s platform technology has both diagnostic and therapeutic applications and has demonstrated the ability to capture more than 100 clinically relevant bacteria, fungi, parasites, toxins and viruses, including SARS-CoV-2. Infectious diseases are a leading cause of death worldwide. COVID-19 has already claimed the lives of over 500,000 U.S. citizens and over 2.4 million worldwide. This major milestone advances BOA’s mission of revolutionizing the fight against infectious disease and sepsis, by providing governments, nurses and doctors with tools and technology to save lives.

When it comes to infectious disease, knowledge is power and speed is paramount. For each hour of delay in treating an advanced case of sepsis, fatality rates increase by up to 8%. BOA’s technology has the potential to effectively manage infectious disease throughout the patient journey—from diagnosis, to tracking to treatment. GARNET also addresses the growing emergence of antibiotic-resistant infection, a significant limitation of existing therapies, and is intended to serve as a medical countermeasure capable of responding to any infectious outbreak, even when the pathogen is unknown.

Click the button below to read the entire Press Release:

Continue Reading The Press Release